Efficacy and Safety of Zoledronic Acid in the Prevention and Treatment of Corticosteroid Induced Osteoporosis
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
The intake of high doses of corticosteroids is known to play an important role in the
weakening of the bones and is thus an increasing fracture risk. Zoledronic acid (Aclasta) is
a drug known for its protective effect in some bone diseases (tumors, paget). This study will
test the safety and efficacy of zoledronic acid in the prevention and treatment of
corticosteroid induced osteoporosis in male and female patients.